Oncology Update: Anamorelin

Prommer, Eric

doi:10.1177/1178224217726336

Cited by 11 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In association with those disorders of metabolic/nutrition pathways, the increase of IL-6 and the decrease of ghrelin are observed characteristically in advanced cancers. It is considered that the inflammatory cytokine IL-6, which cancer cells produce, plays a crucial role to induce cancer cachexia in tumor-host interaction [17][18][19][20]. It has been shown in rodent models that blocking with anti-IL-6 receptor antibody leads to the improvement of cancer cachexia and malnutrition [14].…”

Section: Discussionmentioning

confidence: 99%

Untitled

2020

MCR

View full text Add to dashboard Cite

An immune-modulating diet (IMD), an enteral diet enriched with immunonutrition and whey-hydrolyzed peptides, has been shown to bring an improvement of prognosis by suppressing inflammation after surgery or under stress. In this study, we have experimentally and clinically examined the effect of the IMD in cancer chemotherapy. In experiments using colorectal cancer cell-transplanted mice, the mice fed with the IMD in combination with anti-cancer agent showed significantly to maintain their body weight excluding tumor, and to reduce plasma interleukin-6 (IL-6) levels compared with the control group. Furthermore, normal mice fed with the IMD elevated the level of plasma ghrelin, in particular acyl ghrelin. An clinical trial for a patient with malignant lymphoma revealed that the acyl/desacyl ghrelin ratio and total calorie intake was increased when the patient was supplemented with the IMD in conjunction with chemotherapy. These results suggested that the supplementation of the IMD during cancer chemotherapy might enable to maintain the food intake of the patients through elevating their acyl ghrelin levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Untitled

2020

MCR

View full text Add to dashboard Cite

show abstract

“…Although regulatory agencies approved Anamorelin for cachexia syndrome in Japan ( Wakabayashi, Arai and Inui, 2020 ), the Phase-III ROMANA trial unfortunately failed to reach one of its primary endpoints in Europe. Indeed, Anamorelin administration resulted in improvement of skeletal muscle mass but not function ( Temel et al, 2016 ; Prommer, 2017 ). Beside this failure, Anamorelin remains one of the more promising drug for cancer cachexia so far.…”

Section: Gut and Stomach: Bad Allies In Cancer Cachexiamentioning

confidence: 99%

Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene

Ferrara

Samaden

Ruggieri

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cachexia is a devastating syndrome associated with the end-stage of several diseases, including cancer, and characterized by body weight loss and severe muscle and adipose tissue wasting. Although different cancer types are affected to diverse extents by cachexia, about 80% of all cancer patients experience this comorbidity, which highly reduces quality of life and response to therapy, and worsens prognosis, accounting for more than 25% of all cancer deaths. Cachexia represents an urgent medical need because, despite several molecular mechanisms have been identified, no effective therapy is currently available for this devastating syndrome. Most studies focus on skeletal muscle, which is indeed the main affected and clinically relevant organ, but cancer cachexia is characterized by a multiorgan failure. In this review, we focus on the current knowledge on the multiple tissues affected by cachexia and on the biomarkers with the attempt to define a chronological pathway, which might be useful for the early identification of patients who will undergo cachexia. Indeed, it is likely that the inefficiency of current therapies might be attributed, at least in part, to their administration in patients at the late stages of cachexia.

show abstract

“…Anamorelin is analogous to ghrelin, but with a halflife of almost 7 to 12 hours, therefore, longer than natural ghrelin, 16 and it has been tested as an appetite-stimulating agent, demonstrating its ability to improve anorexia in PC. 4 Prommer, in 2017, carried out an oncological update that aimed to analyze the effect of anamorelin on cachexia, concluding that the drug reverses the symptoms of anorexia and increases lean mass in patients with advanced lung cancer, representing a new option for the management of cancer anorexia-cachexia.…”

Section: Anamorelinmentioning

confidence: 99%

“…4 Prommer, in 2017, carried out an oncological update that aimed to analyze the effect of anamorelin on cachexia, concluding that the drug reverses the symptoms of anorexia and increases lean mass in patients with advanced lung cancer, representing a new option for the management of cancer anorexia-cachexia. 16 The dosage used for anamorelin in the studies was 100 mg/day and the common adverse reactions were hyperglycemia, nausea and edema. 12…”

Section: Anamorelinmentioning

confidence: 99%

Management Approach for Anorexia in Palliative Care: An Integrative Literature Review

Moura

Melo

Chaves

et al. 2020

R.pesq.:cuid.fundam.Online

View full text Add to dashboard Cite

Objetivo: Identificar as evidências científicas acerca das condutas para o manejo da anorexia em cuidados paliativos. Métodos: Trata-se de uma revisão integrativa, cujo levantamento bibliográfico dos dados deu-se através da pesquisa em quatro bases de dados/bibliotecas virtuais. Incluíram-se artigos em português, inglês e espanhol, publicados nos últimos dez anos e com o texto completo disponível. Resultados: Foram elegíveis 25 artigos, e foram atribuídos dois eixos temáticos para melhor ilustrar os dados encontrados: o manejo farmacológico e o não-farmacológico. Corticosteroides, progestinas, anamorelina e dronabinol foram os fármacos mais pesquisados para o controle da anorexia, com maiores evidências de eficácia nos 3 primeiros. No contexto não-farmacológico, o aconselhamento nutricional foi a medida mais indicada, incluindo a fortificação de alimentos e uso de suplementos e a nutrição artificial mais controversa. Conclusão: Os achados desta revisão podem colaborar para a elaboração de protocolos para o manejo da anorexia em cuidados paliativos.

show abstract

Oncology Update: Anamorelin

Cited by 11 publications

References 49 publications

Untitled

Untitled

Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene

Management Approach for Anorexia in Palliative Care: An Integrative Literature Review

Contact Info

Product

Resources

About